A Tumblr Takeover? ...
Health Care: Drugs
Advanced Cell Tech Inc. (ACTC: OTC)
$0.07 0.00 | -0.27%
05/17/13 - 03:59 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.07 |
| 52 Week High | 0.10 |
| 52 Week Low | 0.05 |
| Avg. Daily Vol. (Mil) | 6.81 |
| Beta (3 year) | 1.40 |
| Share Related Items | |
| Mkt Cap (Mil) | 182.40 |
| Shares Out (Mil) | 2,438.53 |
| Float (Mil) | 2,311.28 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.30 |
| Current Ratio | 0.30 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 365.84 |
| Price/Book | 0.00 |
| Price/Cash Flow | -5.30 |
| Per Share Data | |
| Earnings | 0.00 |
| Sales | 0.00 |
| Book Value | 0.00 |
| Cash Flow | -0.01 |
| Business Summary | |
|---|---|
| Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. | |
| General Information | |
| 33 Locke Drive
Marlborough, MA 01752 |
|
| www.advancedcell.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 36 | |
| CEO: Mr. Gary Rabin | |
| Short Interest | |
| Current Month (Mil) | 0.00 |
| Previous Month (Mil) | 0.00 |
| Short Interest Ratio (Days) | 0.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -623.40 |
| Return on Investments | 244.00 |
| Profitability | |
| Gross Margin | 72.70 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ACTC
- Portfolio NameUser Type
- UserKJ Stocks
- UserMark
- UserBiotech88
- UserThe Jayden Project
- Userwright stocks
- UserRimp's Stockpicks
- UserMy Portfolio
- User2
- User1
- UserRAPTOR LAST 2
Latest ACTC Headlines from TheStreet
- Thursday's Small-Cap Winners & Losers 06.21.07 | 04:06 pm
Press Releases for ACTC
- Advanced Cell Technology, Cytomedix And Mesoblast To Provide Corporate And Clinical Updates At Regen Med Investor Day - PR Newswire 04.09.13 | 12:04 pm
- ACT’s Chief Scientific Officer Dr. Robert Lanza To Deliver The Nerem Lecture 2013 At The 17th Annual Hilton Head Workshop - Business Wire 03.22.13 | 08:03 am
- Advanced Cell Technology Receives Approval From Data Safety Monitoring Board (DSMB) To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials - Business Wire 03.14.13 | 08:03 am
- ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People On Stem Cells” - Business Wire 03.12.13 | 08:03 am
- Advanced Cell Technology To Present At BIO-Europe Spring 2013 - Business Wire 03.08.13 | 12:03 pm
- Advanced Cell Technology Announces Fourth-Quarter And Year-end Results - Business Wire 03.07.13 | 04:03 pm
- Advanced Cell Technology To Announce Fourth Quarter And Year-end Results On Thursday March 7th - Business Wire 03.04.13 | 09:03 am
- ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief Of BioResearch Open Access Journal - Business Wire 02.11.13 | 11:02 am
- ACT’s Clinical Partner Receives FDA Approval To Initiate Clinical Trial Using The Company’s HESC-derived Cells To Treat Severe Myopia - Business Wire 02.11.13 | 08:02 am
- Advanced Cell Technology To Present At 15th Annual BIO CEO & Investor Conference - Business Wire 02.08.13 | 08:02 am
Partner Headlines for ACTC
- First patients picked for stem cell vision trials - Reuters 06.16.11 | 09:06 am
- UPDATE 3-US court backs federal embryonic stem cells funds - Reuters 04.29.11 | 02:04 pm
- FDA OKs second Advanced Cell stem cell trial - Reuters 01.03.11 | 11:01 am
- UPDATE 2-Second US company gets stem cell go-ahead - Reuters 11.22.10 | 02:11 pm
- UPDATE 3-First patient treated in Geron stem cell trial - Reuters 10.11.10 | 03:10 pm
- Geron given FDA go-ahead for stem cells trial - Financial Times 07.30.10 | 06:07 pm
